Cinacalcet is efficacious in pediatric dialysis patients

Pediatric Nephrology

Volumn 23, Issue 10, 2008, Pages 1817-1822

  Silverstein, Douglas M ^a   Kher, Kanwal K ^a   Moudgil, Asha ^a   Khurana, Mona ^a   Wilcox, Jennifer ^a   Moylan, Kathleen ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Calcimimetic; Calcium; Parathyroid hormone; Phosphorous; Secondary hyperparathyroidism

Indexed keywords

ALKALINE PHOSPHATASE; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CINACALCET; COLECALCIFEROL DERIVATIVE; GLUCOSE; HEMOGLOBIN; LANTHANUM CARBONATE; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE BINDING AGENT; PHOSPHORUS; POTASSIUM; SODIUM;

ADOLESCENT; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; CALCIUM BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE COUNT; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; LEUKOCYTE COUNT; MALE; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; SHORT COURSE THERAPY; SIDE EFFECT; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TONIC CLONIC SEIZURE;

ADOLESCENT; ALKALINE PHOSPHATASE; CHILD; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; NAPHTHALENES; PARATHYROID HORMONE; RENAL DIALYSIS;

EID: 51549114722     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-007-0742-5     Document Type: Article

References (37)

1. Hsu AC, Kooh SW, Fraser D, Cumming WA, Fornasier VL (1982) Renal osteodystrophy in children with chronic renal failure: An unexpectedly common and incapacitating complication. Pediatrics 70:742-750
2. Sanchez CP (2001) Prevention and treatment of renal osteodystrophy in children with chronic renal insufficiency and end-stage renal disease. Semin Nephrol 21:441-450
3. Salusky IB, Ramirez JA, Oppenheim W, Gales B, Segre GV, Goodman WG (1994) Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 45:253-258
4. Sanchez CP, Salusky IB (1996) The renal bone diseases in children treated with dialysis. Adv Renal Replace Ther 3:14-23
5. Salusky IB, Goodman WG (2003) Renal osteodystrophy in dialyzed children. Miner Electrolyte Metab 17:273-280
6. Urena P, Frazao JM (1990) Calcimimetic agents: Review and perspectives. Kidney Int 63:S91-S96
7. Greenbaum LA, Grenda R, Qiu P, Restaino I, Wojtar A, Paredes A, Benador N, Melnick JZ, Williams LA, Salusky IB (2005) Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis. Pediatr Nephrol 20:622-630
8. Alon U, Davidai G, Bentur L, Berant M, Better OS (1986) Oral calcium carbonate as phosphate-binder in infants and children with chronic renal failure. Miner Electrolyte Metab 12:320-325
9. Salusky IB, Fine RN, Kangarloo H, Gold R, Paunier L, Goodman WG, Brill JE, Gilli G, Slatapolsky E, Coburn JW (1987) "High-dose" calcitriol for control of renal osteodystrophy in children on CAPD. Kidney Int 32:89-95
10. Milliner DS, Zinsmeister AR, Lieberman E, Landing B (1990) Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 38:931-936
11. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000) Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483
12. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, De Vernejoul MC (2004) Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15:1943-1951
13. Ribiero S, Ramos A, Brandao A, Rebelo JR, Guerra A, Resina C, Vila-Lobos A, Carvalho F, Remedio F, Ribiero F (1998) Cardiac valve calcification in haemodialysis patients: Role of calcium-phosphate metabolism. Nephrol Dial Transplant 13:2037-2040
14. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Porter K (2001) Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131-2138
15. Chen RA, Goodman WG (2004) Role of the calcium-sensing receptor in parathyroid gland physiology. Am J Physiol Renal Physiol 286:F1005-F1011
16. Goodman WG (2003) Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials. Pediatr Nephrol 18:1206-1210
17. Drueke TB (2005) Treatment of secondary hyperparathyroidism of dialysis patients with calcimimetics as a valuable addition to established therapeutic means. Pediatr Nephrol 20:399-403
18. Ritz E (2005) Calcimimetics-fooling the calcium receptor. Pediatr Nephrol 20:15-18
19. Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, Barri YM, Cohen RM, Coburn JW (2004) The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13:1017-1024
20. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, Turner SA, Bushinsky DA (2003) The calcimetric AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14:575-583
21. Moe SM, Cunningham J, Bommer J, Adler S, Rosansky SJ, Urena-Torres P, Aibizem MB, Guo MD, Zani VJ, Goodman WG, Sprague SM (2005) Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 20:2186-2193
22. Cnertow GM, Blumenthal S, Turner S, Roppolo M, Stern L, Chi EM, Reed J; Control Investigators (2006) Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate. Clin J Am Soc Nephrol 1:305-312
23. Fukugawa M, Yumati S, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, Koshikawa S; KRN1493 Study Group (2008) Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transpl 23:328-335
24. Naranyan R, Perkins RM, Berbano EP, Yuan CM, Neff RT, Sawyers ES, Yeo FE, Vidal-Trecan GM, Aboott KC (2007) Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: A cost utility analysis. Am J Kidney Dis 49:801-813
25. Lomonte C, Aantoneli M, Losurdo N, Marchio G, Giammaria B, Basile C (2007) Cinacalcet is effective in relapses of secondary hyperparathyroidism after parathyroidectomy. Nephrol Dial Transplant 22:2056-2062
26. Strippoli GF, Palmer S, Tong A, Elder G, Messa P, Craig JC (2006) Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. Am J Kidney Dis 47:715-726
27. Martin KJ, Jüppner H, Sherrado DJ, Goodman WG, Kaplan MR, Nassar G, Campbell P, Curzi M, Chartyan C, McCary LC, Guo MD, Turner SA, Bushinsky DA (2005) First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl. Kidney Int 68:1236-1243
28. Block GA, Martin KJ, De Francisco ALM, Turner SA, Avram M, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516-1525
29. Lindberg JS, Culleton NB, Wong G (2005) Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multi-center study. J Am Soc Nephrol 16:800-807
30. Burton DW, Foster M, Johnson KA, Hiramoto M, Deftos LJ, Terkeltaub R (2005) Chondrocyte calcium-sensing receptor expression is up-regulated in early guinea pig knee osteoarthritis and modulates PTHrP, MMP-13, and TIMP-3 expression. Osteoarthritis Cartilage 13:395-404
31. 2+ sensing receptor activation in the growth plate. FASEB J 18:143-145
32. National Kidney Foundation (2005) Kidney Disease Quality Initiative (K/ DOQI) Clinical Practice Guidelines for Bone Metabolism and Disease in Children With Chronic Kidney Disease Guidelines 1-17
33. Martin KJ, Gonzalez EA, Gellens ME, Hamm LL, Abboud H, Lindberg J (1998) Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2. Am J Kidney Dis 32(Suppl 2):S61-S66
34. Lindberg J, Martin KJ, Gonzalez EA, Acchiardo SR, Valdin JR, Soltanek C (2001) A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol 56:315-323
35. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555-576
36. Goldstein SL, Sorof JM, Brewer ED (1999) Natural logarithmic estimates of Kt/V in the pediatric hemodialysis population. Am J Kidney Dis 33:518-522
37. Hussar DA (2005) New Drugs of 2004. J Am Pharm Assoc (2003) 45:185-218